NCT04955366View on ClinicalTrials.gov

Abatacept Conversion in Kidney Transplantation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

September 22, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Renal Transplant Recipient
Interventions
DRUG

Belatacept

Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg monthly

DRUG

Abatacept

Abatacept is an immunosuppressive medication and will be given SQ at a dose of 125 mg s.c. weekly

Trial Locations (1)

30322

Emory University Hospital (EUH), Atlanta

All Listed Sponsors
lead

Emory University

OTHER